205 related articles for article (PubMed ID: 19362861)
41. [Effects of ovarian carcinoma cells on the maturation and function of human dendritic cells].
Li CD; Zhang WY; Yuan CL; Han LY
Zhonghua Yi Xue Za Zhi; 2009 Mar; 89(9):630-4. PubMed ID: 19595165
[TBL] [Abstract][Full Text] [Related]
42. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity.
Palucka AK; Ueno H; Connolly J; Kerneis-Norvell F; Blanck JP; Johnston DA; Fay J; Banchereau J
J Immunother; 2006; 29(5):545-57. PubMed ID: 16971810
[TBL] [Abstract][Full Text] [Related]
43. Delayed disease progression after allogeneic cell vaccination in hormone-resistant prostate cancer and correlation with immunologic variables.
Michael A; Ball G; Quatan N; Wushishi F; Russell N; Whelan J; Chakraborty P; Leader D; Whelan M; Pandha H
Clin Cancer Res; 2005 Jun; 11(12):4469-78. PubMed ID: 15958632
[TBL] [Abstract][Full Text] [Related]
44. Human monocyte-derived dendritic cells pulsed with wild-type p53 protein efficiently induce CTLs against p53 overexpressing human cancer cells.
Tokunaga N; Murakami T; Endo Y; Nishizaki M; Kagawa S; Tanaka N; Fujiwara T
Clin Cancer Res; 2005 Feb; 11(3):1312-8. PubMed ID: 15709203
[TBL] [Abstract][Full Text] [Related]
45. [Functional changes of dendritic cells after infection by recombinant retrovirus carrying human telomerase reverse transcriptase gene fragment].
Hu GF; Sun LS; Jin H; Ou CS; Jiang YP; Pang JX
Nan Fang Yi Ke Da Xue Xue Bao; 2006 Apr; 26(4):394-7. PubMed ID: 16624735
[TBL] [Abstract][Full Text] [Related]
46. Numerical and functional assessment of blood dendritic cells in prostate cancer patients.
Wilkinson R; Kassianos AJ; Swindle P; Hart DN; Radford KJ
Prostate; 2006 Feb; 66(2):180-92. PubMed ID: 16173035
[TBL] [Abstract][Full Text] [Related]
47. Potential therapeutic value of dendritic cells loaded with NY‑ESO‑1 protein for the immunotherapy of advanced hepatocellular carcinoma.
Chen Y; Huang A; Gao M; Yan Y; Zhang W
Int J Mol Med; 2013 Dec; 32(6):1366-72. PubMed ID: 24085111
[TBL] [Abstract][Full Text] [Related]
48. Myeloid dendritic cells loaded with dendritic tandem multiple antigenic telomerase reverse transcriptase (hTERT) epitope peptides: a potentially promising tumor vaccine.
Niu BL; Du HM; Shen HP; Lian ZR; Li JZ; Lai X; Wei SD; Zou LQ; Gong JP
Vaccine; 2012 May; 30(23):3395-404. PubMed ID: 22480929
[TBL] [Abstract][Full Text] [Related]
49. Immunoregulatory effects of freeze injured whole tumour cells on human dendritic cells using an in vitro cryotherapy model.
Ismail M; Morgan R; Harrington K; Davies J; Pandha H
Cryobiology; 2010 Dec; 61(3):268-74. PubMed ID: 20863822
[TBL] [Abstract][Full Text] [Related]
50. Improved clinical outcome in indolent B-cell lymphoma patients vaccinated with autologous tumor cells experiencing immunogenic death.
Zappasodi R; Pupa SM; Ghedini GC; Bongarzone I; Magni M; Cabras AD; Colombo MP; Carlo-Stella C; Gianni AM; Di Nicola M
Cancer Res; 2010 Nov; 70(22):9062-72. PubMed ID: 20884630
[TBL] [Abstract][Full Text] [Related]
51. Dendritic cells transfected with lentiviral vector-encoding hTERT peptide augment antitumor T cell response in vitro.
Cui J; Cui L; Liu Q; Sun Q
Mol Med Rep; 2012 Jan; 5(1):103-7. PubMed ID: 21971748
[TBL] [Abstract][Full Text] [Related]
52. Cytotoxic immunotherapy strategies for cancer: mechanisms and clinical development.
Aguilar LK; Guzik BW; Aguilar-Cordova E
J Cell Biochem; 2011 Aug; 112(8):1969-77. PubMed ID: 21465529
[TBL] [Abstract][Full Text] [Related]
53. Clinical scale electroloading of mature dendritic cells with melanoma whole tumor cell lysate is superior to conventional lysate co-incubation in triggering robust in vitro expansion of functional antigen-specific CTL.
Wolfraim LA; Takahara M; Viley AM; Shivakumar R; Nieda M; Maekawa R; Liu LN; Peshwa MV
Int Immunopharmacol; 2013 Mar; 15(3):488-97. PubMed ID: 23474736
[TBL] [Abstract][Full Text] [Related]
54. Immunotherapy of cancer with dendritic cells loaded with tumor antigens and activated through mRNA electroporation.
Van Nuffel AM; Corthals J; Neyns B; Heirman C; Thielemans K; Bonehill A
Methods Mol Biol; 2010; 629():405-52. PubMed ID: 20387165
[TBL] [Abstract][Full Text] [Related]
55. Identification of AKAP-4 as a new cancer/testis antigen for detection and immunotherapy of prostate cancer.
Chiriva-Internati M; Yu Y; Mirandola L; D'Cunha N; Hardwicke F; Cannon MJ; Cobos E; Kast WM
Prostate; 2012 Jan; 72(1):12-23. PubMed ID: 21520158
[TBL] [Abstract][Full Text] [Related]
56. Tumor cell lysates as immunogenic sources for cancer vaccine design.
González FE; Gleisner A; Falcón-Beas F; Osorio F; López MN; Salazar-Onfray F
Hum Vaccin Immunother; 2014; 10(11):3261-9. PubMed ID: 25625929
[TBL] [Abstract][Full Text] [Related]
57. WAVE3 is associated with invasiveness in prostate cancer cells.
Fernando HS; Sanders AJ; Kynaston HG; Jiang WG
Urol Oncol; 2010; 28(3):320-7. PubMed ID: 19395286
[TBL] [Abstract][Full Text] [Related]
58. Characterization of interferon-γ-treated melanoma tumor cells for use in dendritic cell-based immunotherapy.
Cornforth AN; Fowler AW; Carbonell DJ; Fan E; Dillman RO
Cancer Biother Radiopharm; 2011 Jun; 26(3):345-51. PubMed ID: 21711093
[TBL] [Abstract][Full Text] [Related]
59. Enhanced antitumor effects by the coculture of allotumor RNA-pulsed dendritic cells with autologous cytokine-induced killer cells on hormone-refractory prostate cancer.
Pang J; Gao X; Liu X; Wang K; Zhang Y; Feng L; Zhan H
Cancer Invest; 2007; 25(7):527-34. PubMed ID: 17952744
[TBL] [Abstract][Full Text] [Related]
60. Antitumor effect of dendritic cells transfected with prostate-specific membrane antigen recombinant adenovirus on prostate cancer: An in vitro study.
Meng FD; Wang S; Jiang YH; Sui CG
Mol Med Rep; 2016 Mar; 13(3):2124-34. PubMed ID: 26783185
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
